Skip to Content

Acalabrutinib Dosage

Medically reviewed by Drugs.com. Last updated on Nov 29, 2017.

Applies to the following strengths: 100 mg

Usual Adult Dose for Lymphoma

100 mg orally approximately every 12 hours
Duration of Therapy: Until disease progression or unacceptable toxicity

Comments: The indication for this drug is approved under accelerated approval based on overall response rate; continued approval may be contingent upon verification and description of clinical benefit in confirmatory trials.

Use: Treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.

Renal Dose Adjustments

Data not available

Liver Dose Adjustments

Data not available

Dose Adjustments

CONCOMITANT USE WITH CYP450 3A INDUCERS OR INHIBITORS:
-Strong Inducer: Avoid concomitant use; if concomitant use necessary, increase dose of this drug to 200 mg two times a day.
-Strong Inhibitor: Avoid concomitant use; if inhibitor will be used short-term (e.g., anti-infectives for up to 7 days), interrupt dosing of this drug.
-Moderate Inhibitor: Reduce dose frequency of this drug to 100 mg once a day.

CONCOMITANT USE WITH GASTRIC ACID REDUCING AGENTS:
-Antacid: Separate dosing by at least 2 hours.
-H2-Receptor Antagonist: Administer this drug 2 hours before taking a H2-receptor antagonist.
-Proton Pump Inhibitor: Avoid concomitant use.

MANAGEMENT OF ADVERSE REACTIONS (Grade 3 or Greater Non-Hematologic Toxicities; Grade 3 Thrombocytopenia with Bleeding; Grade 4 Thrombocytopenia; OR Grade 4 Neutropenia Lasting Longer Than 7 Days):
-First and Second Occurrence: Interrupt dosing; resume the usual dose of 100 mg twice a day once toxicity has resolved to Grade 1 or baseline level.
-Third Occurrence: Interrupt dosing; reduce the dose to 100 mg per day once toxicity has resolved to Grade 1 or baseline level.
-Fourth Occurrence: Discontinue this drug.

Precautions

Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration Advice:
-Advise patients to swallow drug capsule whole with water, with or without food.
-Instruct patients not to open, break, or chew drug capsules.
-If a dose is missed by less than 3 hours, advise patients that they may still take that dose; if more than 3 hours have elapsed, instruct patients to skip that dose and to take the next dose at the regularly scheduled time.
-Warn patients that they should not take extra drug capsules to make up for a missed dose.

Storage Requirements:
-Store at 20 to 25 degrees Celsius (68 to 77 degrees Fahrenheit); excursions permitted to 15 to 30 degrees Celsius (59 to 86 degrees Fahrenheit).

Monitoring:
-Cardiovascular: Signs/symptoms of atrial fibrillation and atrial flutter; signs of bleeding
-Hematologic: Periodic blood counts
-Infections/Infestations: Signs/symptoms of infection

Patient Advice:
-During treatment, use sun protection whenever you're exposed to sunlight as there have been reports of some patients experiencing new cancers (including skin cancer) while taking this drug.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide